Kinetic Screening of Nuclease Activity using Nucleic Acid Probes
November 1st, 2019
7.7K views
Altered nuclease activity has been associated with different human conditions, underlying its potential as a biomarker. The modular and easy to implement screening methodology presented in this paper allows the selection of specific nucleic acid probes for harnessing nuclease activity as a biomarker of disease.
Overview
This protocol provides a powerful alternative for screening nuclease activity as a biomarker of disease, utilizing an easy-to-implement methodology suitable for researchers with varying expertise in nucleic acid probes. The technique allows for the selection of nucleic acid probes that can identify both known and unknown nuclease activities.
Key Study Components
Area of Science
- Biomarker discovery
- Nuclease activity screening
- Nucleic acid probe technology
Background
- Altered nuclease activity is linked to various human conditions.
- Nuclease activity has potential as a biomarker for disease.
- The methodology is designed to be modular and flexible.
- High reproducibility and ease of use are key advantages.
Purpose of Study
- To present a screening methodology for nuclease activity.
- To facilitate the identification of nucleic acid probes.
- To provide a user-friendly approach for researchers.
Methods Used
- Designing an oligonucleotide library with DNA and RNA sequences.
- Preparing oligonucleotide probes in Tris-EDTA buffer.
- Using a dynamic interaction between probes and nucleases.
- Demonstration of the protocol by laboratory personnel.
Main Results
- The methodology allows for the identification of various nuclease activities.
- Probes can be tailored for specific applications.
- Demonstrated flexibility and reproducibility in results.
- Accessible for researchers with different levels of expertise.
Conclusions
- The presented methodology is a significant advancement in biomarker screening.
- It offers a practical solution for researchers in the field.
- Future applications could enhance understanding of disease mechanisms.
Frequently Asked Questions
What is the main advantage of this methodology?
The main advantage is its ability to select nucleic acid probes that can identify both known and unknown nuclease activities.
Who can use this protocol?
This protocol is designed to be user-friendly, making it accessible even for researchers who are not specialized in nucleic acid probes.
What types of sequences should be included in the oligonucleotide library?
Include at least one DNA and one RNA random sequence containing a combination of adenine, guanine, cytosine, and thymine or uracil.
How should oligonucleotide probes be prepared?
Spin down the lyophilized oligonucleotide probes and dilute each in Tris-EDTA buffer at a concentration of 500 picomolar per microliter.
What is the role of the dynamic interaction in this methodology?
The dynamic interaction between the probes and nucleases is crucial for identifying the nuclease activities effectively.
Who demonstrated the protocol in the study?
The demonstration was performed by Khadija, a Masters student, and Baris, a postdoc from the laboratory.
Executive Industry Relevance
Nuclease activity serves as a promising biomarker for disease conditions such as bacterial infections and cancer, yet robust screening methods remain limited. This protocol enables iterative selection of nucleic acid probes to differentiate pathological from healthy states, supporting diagnostic tool development. Its flexibility, reproducibility, and ease of use position it as a scalable approach for target validation in early discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by identifying nuclease activity patterns linked to disease mechanisms.
- Operational Value: Supports biological de-risking through functional validation of nuclease targets using probe-nuclease dynamic interactions.
- Predictive Value: Facilitates portfolio triage by identifying probe candidates with enhanced specificity for disease-associated nucleases.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems for downstream workflows by establishing reproducible nuclease activity readouts.
- Operational Value: Ensures assay standardization through kinetic fluorescence measurements in controlled buffer conditions.
- Scalability Value: Enables screening readiness and platform reuse via modular probe library design and iterative refinement.
Translational & Preclinical Research
- Scientific Value: Supports disease-relevant systems by linking nuclease activity to pathological conditions like Salmonella infection.
- Operational Value: Ensures translational continuity from discovery through preclinical validation via consistent probe performance metrics.
- Risk-Adjusted Advancement: Informs go/no-go decisions by quantifying nuclease substrate preferences across chemically modified nucleotides.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation to lead identification, enabling hypothesis testing and pathway clarification through quantitative nuclease profiling.
- Discovery Biology: Supports hypothesis testing by measuring nuclease activity as a functional readout of target engagement in disease models.
- Screening: Delivers assay readiness through reproducible kinetic graphs generated from relative fluorescence units over time.
- Analytics: Provides quantitative dependent variable measurements (fluorescence intensity) enabling comparison of probe performance across conditions.
- Translational Research: Connects to preclinical continuity by identifying probe candidates with disease-specific nuclease recognition capabilities.
- Enterprise Reuse: Functions as a reusable capability for iterative probe library optimization across multiple screening rounds.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through reduction of mechanistic ambiguity in nuclease-substrate interactions.
- Operational Value: Standardization, reproducibility, and scalability via defined probe concentrations and kinetic measurement protocols.
- Strategic Value: Better go/no-go decisions, capital efficiency, and reduced late-stage biological risk by enabling early biomarker-linked target selection.
- Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on quantitative nuclease activity profiles.
Implementation Considerations
- Requires expertise in nucleic acid probe design and fluorescence-based kinetic assays.
- Dependent on fluorometer instrumentation with temperature control and kinetic acquisition software.
- Necessitates cross-team standardization of probe preparation and buffer conditions for reproducible results.
- Requires adaptation considerations when applying to different model systems or nuclease types.
- Practical limitations include the need for multiple screening rounds to refine probe specificity, as supported by source material.
Biopharma FAQs
Why does null hypothesis testing matter for target validation?
Null hypothesis testing helps determine whether observed nuclease activity differences between pathological and healthy conditions are statistically significant, supporting confident target selection.
How does independent variable isolation fit the discovery pipeline?
Isolating the probe type as the independent variable enables clear attribution of changes in fluorescence to specific nuclease-substrate interactions, improving target validation rigor.
What quantitative dependent variable measurements enable?
Measuring fluorescence intensity over time generates kinetic graphs that quantify nuclease activity, enabling comparison of probe performance across bacterial strains or conditions.
Why do replication requirements matter for cross-functional collaboration?
Replication ensures consistent nuclease activity readouts across experiments, allowing discovery, assay development, and translational teams to rely on standardized data for decision-making.
What statistical analysis capabilities are required before implementation?
Teams require the ability to analyze kinetic data, including relative fluorescence units over time, to assess significant differences in nuclease activity between samples and controls.
